 VANCOUVER, British Columbia and SEATTLE, March 01, 2021 GLOBE NEWSWIRE -- Chinook Therapeutics, Inc. NASDAQ: KDNY and Evotec SE today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases. Based on Evotecs proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover precision medicines for PKD, lupus nephritis, IgA nephropathy and other primary glomerular diseases. The collaboration will also involve further characterization of pathways and patient stratification strategies for programs currently in Chinooks clinical and preclinical pipeline. 